OptimizeRx Co. (NASDAQ:OPRX) Director Gus D. Halas purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were purchased at an average cost of $9.68 per share, for a total transaction of $48,400.00.

OptimizeRx stock traded up $0.08 during midday trading on Friday, hitting $9.73. 75,600 shares of the stock were exchanged, compared to its average volume of 92,063. OptimizeRx Co. has a 1 year low of $8.92 and a 1 year high of $17.24. The firm has a market cap of $141.60 million, a P/E ratio of 193.80 and a beta of 0.42. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.00 and a quick ratio of 7.00. The company has a 50 day moving average price of $12.92 and a two-hundred day moving average price of $14.39.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.15). The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $7.21 million. OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. As a group, analysts predict that OptimizeRx Co. will post -0.04 EPS for the current year.

Several research firms recently issued reports on OPRX. Zacks Investment Research downgraded shares of OptimizeRx from a “hold” rating to a “sell” rating in a research note on Tuesday, November 5th. ValuEngine raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, B. Riley dropped their price target on shares of OptimizeRx from $26.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Park West Asset Management LLC increased its position in shares of OptimizeRx by 14.0% in the 2nd quarter. Park West Asset Management LLC now owns 1,088,088 shares of the company’s stock worth $17,627,000 after purchasing an additional 133,238 shares during the last quarter. BlackRock Inc. increased its position in shares of OptimizeRx by 2,111.6% in the 2nd quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock worth $9,839,000 after purchasing an additional 579,833 shares during the last quarter. Vanguard Group Inc. increased its position in shares of OptimizeRx by 22.2% in the 2nd quarter. Vanguard Group Inc. now owns 511,060 shares of the company’s stock worth $8,279,000 after purchasing an additional 93,015 shares during the last quarter. Wasatch Advisors Inc. increased its position in shares of OptimizeRx by 24.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 404,873 shares of the company’s stock worth $6,559,000 after purchasing an additional 78,816 shares during the last quarter. Finally, Calamos Advisors LLC increased its position in shares of OptimizeRx by 17.0% in the 3rd quarter. Calamos Advisors LLC now owns 312,764 shares of the company’s stock worth $4,529,000 after purchasing an additional 45,548 shares during the last quarter. 57.60% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Story: QQQ ETF

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.